These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 18056047)
21. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505 [TBL] [Abstract][Full Text] [Related]
22. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Harris ST; Blumentals WA; Miller PD Curr Med Res Opin; 2008 Jan; 24(1):237-45. PubMed ID: 18047776 [TBL] [Abstract][Full Text] [Related]
23. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Chesnut CH Drugs; 2006; 66(10):1351-9. PubMed ID: 16903769 [TBL] [Abstract][Full Text] [Related]
24. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Frampton JE; Perry CM Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707 [TBL] [Abstract][Full Text] [Related]
25. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis]. Reginster JY Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748 [TBL] [Abstract][Full Text] [Related]
26. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Bauss F; Russell RG Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712 [TBL] [Abstract][Full Text] [Related]
27. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Sambrook P; Cranney A; Adachi JD Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751 [TBL] [Abstract][Full Text] [Related]
28. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160 [TBL] [Abstract][Full Text] [Related]
29. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Emkey RD; Ettinger M Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937 [TBL] [Abstract][Full Text] [Related]
30. Effects of ibandronate on bone quality: preclinical studies. Bauss F; Dempster DW Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333 [TBL] [Abstract][Full Text] [Related]
31. Ibandronate: A Review in Japanese Patients with Osteoporosis. Keating GM Drugs Aging; 2016 Apr; 33(4):295-303. PubMed ID: 26915075 [TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. Ettinger MP; Felsenberg D; Harris ST; Wasnich R; Skag A; Hiltbrunner V; Wilson K; Schimmer RC; Miller PD J Rheumatol; 2005 Oct; 32(10):1968-74. PubMed ID: 16206354 [TBL] [Abstract][Full Text] [Related]
33. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Guay DR Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795 [TBL] [Abstract][Full Text] [Related]
34. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358 [TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates for prevention of postmenopausal osteoporosis. Ravn P Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721 [TBL] [Abstract][Full Text] [Related]
37. Drug insight: Bisphosphonates for postmenopausal osteoporosis. Chapurlat RD; Delmas PD Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286 [TBL] [Abstract][Full Text] [Related]
38. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016 [TBL] [Abstract][Full Text] [Related]
39. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Sebba AI Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784 [TBL] [Abstract][Full Text] [Related]
40. Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. Bala Y; Kohles J; Recker RR; Boivin G Calcif Tissue Int; 2013 Jan; 92(1):6-14. PubMed ID: 23090678 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]